Table 1.

Initial dose‐volume constraints and priorities for IMRT and VMAT optimization

Structure	Dose‐volume Constraints	Relative Priority
PTV	${\mathrm{D}}_{100}\ge 95\%$;${\mathrm{D}}_{\text{max}}\le 105\%$	80–120
CTV	${\mathrm{D}}_{100}\ge 98\%$;${\mathrm{D}}_{\text{max}}\le 102\%$	120–130
	${\mathrm{D}}_{\text{max}}\le 70\%$;	150
Skin	${\mathrm{V}}_{50\%}{\le }^{2\%}$	80
ILB	${\mathrm{V}}_{100\%}\ge 2\%–7\%$; ${\mathrm{V}}_{50\%}\ge 10\%–15\%$; ${\mathrm{V}}_{20\%}\le 20\%‐30\%$;	50
CB	${\mathrm{D}}_{\text{max}}\le 1\%$;	30
Heart	${\mathrm{D}}_{\text{max}}\le 1\%$;	30
ILL	${\mathrm{D}}_{\text{max}}\ge 20\%–30\%$; ${\mathrm{V}}_{10\%}\le 2\%–7\%$	30
Normal tissue	Doses between 2 mm and 2 cm from PTV boundary to fall off from 100% to 50% of prescription	80